EUVIMEDEUVIMED entdecken
Crossref

Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population

Prowpanga Udompap iD, Terry M Therneau, Rachel E Canning, Joanne T Benson, Alina M Allen iD

Hepatology · 2023

DOI: 10.1002/hep.32739 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology, 2023. Verfasst von Prowpanga Udompap und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology , Mayo Clinic , Rochester , Minnesota , USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques, Diabetes Mellitus. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims: The American Gastroenterological Association (AGA) recently launched the Clinical Care Pathway for the Risk Stratification and Management of Patients with NAFLD to identify adults with significant fibrosis. We aimed to examine this pathway’s performance in the US population. Approach and Results: Using the 2017–2018 National Health and Nutrition Examination Survey data, we identified participants aged ≥18 with available Fibrosis‐4 (FIB‐4) score and liver stiffness measurement (LSM) in the absence of other liver diseases. Based on the AGA clinical pathway, FIB‐4 < 1.3 and LSM < 8 kilopascals (kPa) by vibration‐controlled transient elastography (VCTE) are associated with low risk of significant fibrosis. Using these cutoffs, we examined the pathway performance using negative predictive value (NPV) and positive predictive value (PPV) and explored alternative risk‐stratification strategies. There were 2322 participants with available data (projected to 94.2 million US adults). The NPV of LSM ≥ 8 kPa among those with FIB‐4 < 1.3 was 90%, whereas the PPV among those with FIB‐4 1.3–2.67 was 13%. As diabetes was a strong predictor of fibrosis, we propose a simple, alternative strategy to eliminate the indeterminate FIB‐4 range and perform VCTE in those with FIB‐4 ≥ 1.3 and diabetes. This strategy would decrease the number of VCTEs from 14.5 to 4.9 million and increase PPV from 13% to 33% without compromising the NPV among those who did not undergo VCTE. Conclusion: The implementation of the current AGA clinical pathway would lead to overutilization of VCTE. An alternative strategy using FIB‐4 ≥ 1.3 and diabetes to select adults undergoing second‐line testing will improve this pathway’s performance and minimize unnecessary VCTEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseElasticity Imaging TechniquesDiabetes MellitusAdultHumansUnited StatesCritical PathwaysLiver CirrhosisNutrition SurveysProspective StudiesBiopsySeverity of Illness IndexFibrosisRisk AssessmentLiver

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology , Mayo Clinic , Rochester , Minnesota , USA.
  • Department of Quantitative Health Sciences , Mayo Clinic , Rochester , Minnesota , USA.

ORCID-Profile: Prowpanga Udompap, Alina M Allen

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Udompap, P., Therneau, T. M., Canning, R. E., Benson, J. T., & Allen, A. M. (2023). Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population. Hepatology. https://doi.org/10.1002/hep.32739

Vancouver

Udompap P, Therneau TM, Canning RE, Benson JT, Allen AM. Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population. Hepatology. 2023. doi:10.1002/hep.32739

BibTeX
@article{Udompap2023,
  author = {Udompap, Prowpanga and Therneau, Terry M and Canning, Rachel E and Benson, Joanne T and Allen, Alina M},
  title = {Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population},
  journal = {Hepatology},
  year = {2023},
  doi = {10.1002/hep.32739}
}
Kostenlos starten →